SEARCH

SEARCH BY CITATION

References

  • 1
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
  • 2
    Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. HEPATOLOGY 2010; 51: 1274-1283.
  • 3
    Bruix J, Sherman M. Management of hepatocellular carcinoma. HEPATOLOGY 2005; 42: 1208-1236.
  • 4
    Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-4300.
  • 5
    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
  • 6
    Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
  • 7
    EU Summary of Product Characteristics for Nexavar, November 2010, Bayer Schering Pharma AG, Berlin, Germany.
  • 8
    Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965-972.
  • 9
    Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 2010; 303: 1180-1187.
  • 10
    Ware JH Hamel MB. Pragmatic trials—guides to better patient care? N Engl J Med 2011; 364: 1685-1687.
  • 11
    von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Ann Intern Med 2007; 147: 163-194.
  • 12
    Lindor RA, Lindor KD. The value of observational research in liver diseases. HEPATOLOGY 2011; 53: 1-3.
  • 13
    Llovet J, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
  • 14
    Agenzia Italiana del Farmaco. Registro farmaci oncologici sottoposti a monitoraggio. http://antineoplastici.agenziafarmaco.it/normativa_registro_trast.htm. Accessed September 2011.
  • 15
    Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649.
  • 16
    Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
  • 17
    Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS. http://ctep.cancer.gov. Published March 31, 2003 and August 9, 2006. Accessed September 2011.
  • 18
    Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
  • 19
    Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
  • 20
    Sangiovanni A, Manini MA, Iavarone M, Romeo R, Forzenigo LV, Fraquelli M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010; 59: 638-644.
  • 21
    Cammà C, Di Marco V, Cabibbo G, Latteri F, Sandonato L, Parisi P, et al. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther 2008; 28: 62-75.
  • 22
    Leoni S, Piscaglia F, Golfieri R, Camaggi V, Vidili G, Pini P, et al. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol 2010; 105: 599-609.
  • 23
    Zavaglia C, Corso R, Rampoldi A, Vinci M, Belli LS, Vangeli M, et al. Is percutaneous radiofrequency thermal ablation of hepatocellular carcinoma a safe procedure? Eur J Gastroenterol Hepatol 2008; 20: 196-201.
  • 24
    Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian center. Gut 2005; 54: 411-418.
  • 25
    Villa E, Colantoni A, Cammà C, Grottola A, Buttafoco P, Gelmini R, et al. Estrogen receptor classification for hepatocellular carcinoma: comparison with clinical staging systems. J Clin Oncol 2003; 21: 441-446.
  • 26
    Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009; 43: 489-495.
  • 27
    Ozenne V, Paradis V, Pernot S, Castelnau C, Vullierme MP, Bouattour M, et al. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 2010; 22: 1106-1110.
  • 28
    Sch¨tte K, Zimmermann L, Bornschein J, Csepregi A, Rühl R, Ricke J, et al. Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis. Digestion 2011; 83: 275-282.
  • 29
    Ogasawara S, Kanai F, Obi S, Sato S, Yamaguchi T, Azemoto R, et al. Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma. Hepatol Int 2011; 5: 850-856.
  • 30
    Maitland ML, Kasza KE, Karrison T, Moshier K, Sit L, Black HR, et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res 2009; 15: 6250-6257.
  • 31
    Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, et al. Phase III study of sorafenib in patients in Japan and Korea with advanced hepatocellular carcinoma (HCC) treated after transarterial chemoembolization (TACE). Presented at: 2010 Gastrointestinal Cancers Symposium; Januaary 22-24, 2010; Orlando, FL. Abstract LBA128.
  • 32
    Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC) according to baseline status: subset analyses of the Phase III sorafenib HCC assessment randomized protocol (SHARP) trial. Lancet Oncol. In press.
  • 33
    Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ, de Lope CR, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009; 115: 616-623.
  • 34
    Collins JM. Pharmacology and drug development. J Natl Cancer Inst 1988; 80: 790-792.
  • 35
    Bronowicki JP, Lencioni R, Venook A, Marrero J, Kudo M, Ye SL, et al. GIDEON (Global Investigation of the therapeutic Decision in hepatocellular carcinoma and Of its treatment with sorafeNIB) study first interim results: sorafenib dosing across regions and disease subgroups. 46th Annual Meeting of the European Association for the Study of the Liver 2011. J Hepatol 2011; 54( suppl 1): A81.